Skip to content

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512279-10-00
Acronym
GS-US-595-6184
Enrollment
758
Registered
2024-10-22
Start date
2024-11-25
Completion date
Unknown
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple Negative Breast Cancer

Brief summary

iDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, or invasive contralateral breast cancer.

Detailed description

OS is defined as the time from the date of randomization until death due to any cause., dDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): distant recurrence, or second primary invasive cancer., RFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, Incidence of TEAEs and clinical laboratory abnormalities, TTW of QoL based on FACT-B Trial Outcome Index (TOI) score

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGTrodelvy 200 mg powder for concentrate for solution for infusion

Sponsors

Gilead Sciences Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
iDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, or invasive contralateral breast cancer.

Secondary

MeasureTime frame
OS is defined as the time from the date of randomization until death due to any cause., dDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): distant recurrence, or second primary invasive cancer., RFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, Incidence of TEAEs and clinical laboratory abnormalities, TTW of QoL based on FACT-B Trial Outcome Index (TOI) score

Countries

Belgium, France, Germany, Ireland, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026